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Late abdominal aortic aneurysm enlargement after
endovascular repair with the Excluder device
Jae-Sung Cho, MD, Ellen D. Dillavou, MD, Robert Y. Rhee, MD, and Michel S. Makaroun, MD,
Pittsburgh, Pa
Objectives: Behavior of the abdominal aortic aneurysm (AAA) sac after endovascular abdominal aortic aneurysm repair
(EVAR) is graft-dependent. The Excluder endograft has been associated with less sac regression than some other stent
grafts. Long-term follow-up has not been reported.
Methods: Between May 1999 and July 2002, 50 patients underwent EVAR with the Excluder bifurcated endoprosthesis.
These patients were followed up prospectively with computed tomography (CT) at 1, 6, and 12 months and yearly
thereafter. One immediate conversion to open surgery and three deaths occurred within 6 months. One additional patient
was lost to follow-up. The remaining 45 patients, 35 men and 10 women, were followed up for at least 1 year, and form
the basis for this report. Their mean age was 73  5.5 years. The minor axis diameter at the largest area of the AAA on
CT examination was compared with the baseline measurement at 1 month and to the smallest size previously recorded
during follow-up. Change in sac size of 5 mm or greater was considered significant. Mean follow-up was 2.7  1.2 years
(range, 1-4 years). Nominal variables were compared with the 2 test, and continuous variables with the Student t test.
Results: A significant decrease in average AAA sac diameter was observed at 6-month, 1-year, and 2-year follow-up. These
differences were lost by the 3-year evaluation, because of delayed sac growth (n  9) and re-expansion of once shrunken
aneurysms (n  3). The probability of freedom from sac growth or re-expansion at 4 years was only 43%. At last
follow-up, sac expansion occurred in the absence of active endoleak in nine patients. Type II endoleak was associated with
sac expansion in three patients (P  .003), resulting in one conversion to open surgery after the 4-year follow-up. No
graft migrations, AAA ruptures, or aneurysm-related deaths were noted.
Conclusions: Late aneurysm sac growth or re-expansion after EVAR with the Excluder device is common, even in the
absence of endoleak. Although the incidence of important clinical sequelae is low at this point, the incidence of aneurysm
expansion should be taken into consideration during the risk-benefit assessment before EVAR repair with the Excluder
device. (J Vasc Surg 2004;39:1236-42.)Since it was first reported in 1991,1 endovascular repair
(EVAR) of abdominal aortic aneurysms (AAA) has resulted
in the introduction of many commercial devices intended
for the treatment of aneurysmal disease. To date four
endograft devices (Ancure, Guidant; AneuRx, Medtronic/
AVE; Excluder, W. L. Gore & Associates; Zenith, Cook)
have been approved by the Food and Drug Administration
(FDA). Three remain commercially available.
As midterm and long-term results are emerging, de-
vice-specific clinical outcomes with respect to frequency of
endoleak, incidence of device migration, risk for limb
thrombosis, and change in aneurysm sac size have been
recognized. Each device has been associated with disparate
long-term results. Previous reports have suggested that the
type of endograft is strongly correlated with the likelihood
of sac regression.2 While shrinkage of the aneurysm sac
after EVAR may be desirable, a stable aneurysm has never
been linked to any untoward effects. Sac enlargement,
however, implies elevated pressure in the aneurysm sac, and
so far has been associated mainly with endoleak. Few iso-
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have been documented and linked to the presence of a sac
hygroma.3,4 The exact extent of this phenomenon is not
known. We reviewed our experience with the first 50
patients to determine the frequency of late sac enlargement
after EVAR with the Excluder device.
PATIENTS AND METHODS
Between May 1999 and July 2002, 50 patients under-
went EVAR with the Excluder bifurcated endoprosthesis at
the University of Pittsburgh Medical Center. All patients
were part of the multiple-phase trials of the device before
FDA approval, and signed a research informed consent
form. All data were and continue to be collected prospec-
tively, according to the trial protocols. The institutional
review board at the University of Pittsburgh School of
Medicine approved all the multiphase trial protocols.
All patients underwent preoperative spiral computed
tomography (CT) with 2.5 mm collimation. Preoperative
angiography was used only when length measurements
could not be accurately determined from CT images and in
cases of unusual anatomy. Postoperative CT scans were
obtained with and without contrast material enhancement
at 1, 6, and 12 months, and yearly thereafter. Four-view
plain radiographs were also obtained at each follow-up visit,
and were evaluated for modular disconnection or device
migration.
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of the aneurysm was in accordance with the Society for
Vascular Surgery reporting standards for endovascular aor-
tic aneurysm repair.5 To avoid interobserver variability all
measurements were prospectively performed by the senior
author (M.S.M.), using digital electronic calipers on a
computer workstation with commercially available software
(Stentor). Aneurysm sac size was defined as the minor axis
on the largest axial cut of the aneurysm on the two-
dimensional CT scan. The minor axis was chosen to avoid
overestimation of AAA size due to tortuosity of the aorta.6
The 1-month postoperative CT scan served as the reference
scan against which all subsequent measurements were com-
pared to determine aneurysm sac expansion or shrinkage.
Changes of 5 mm or more in the minor axis were consid-
ered significant for either enlargement or shrinkage.7 Be-
cause some patients exhibited an initial reduction in size
followed by later enlargement, this phenomenon was re-
ferred to as re-expansion. The re-expansion was also con-
sidered significant at 5 mm above the smallest measured
diameter during follow-up.
The presence or absence of endoleak was determined
from CT scans with and without contrast enhancement.
Patients with persistent endoleak after 6 months of obser-
vation or with delayed-onset endoleak underwent angiog-
raphy and, when feasible, coiling of the responsible branch
vessels. Those with sac expansion and no demonstrable
endoleak were followed up with CT scans at closer inter-
vals. Angiography was performed in two such patients at
3.5 and 4 years, respectively, to look for occult endoleak;
none was detected. Graft migration was defined as longitu-
dinal movement in the attachment sites of at least 10 mm.
Nominal variables were compared with the 2 test, and
continuous variables with the Student t test. Results are
reported as mean  SD.
RESULTS
Clinical results. There were no perioperative deaths.
One patient underwent immediate open conversion when a
left renal artery was inadvertently covered by an aortic
extender placed in an angulated neck to achieve a proximal
seal. No limb occlusion, aneurysm rupture, graft migration,
or limb dislocation was noted during follow-up. One pa-
tient underwent placement of an aortic cuff extender at 1
year, to reinforce the severely angulated proximal attach-
ment site. Three patients died before reaching 6-month
follow-up, from renal-related and cardiac-related causes.
One additional patient was lost to follow-up. The remain-
ing 45 patients (35 men, 10 women; mean age, 73  5.5
years) completed at least 12 months of follow-up, and form
the basis for the size change analysis. Late deaths occurred
in seven patients during follow-up, from unrelated causes.
Four additional patients withdrew from the study because
of health-related and geography-related issues. The last CT
images were obtained at a mean of 2.8 1.2 years. Twenty-
eight patients (62%) were followed up for 3 or more years,
and 19 patients (42%) for 4 years.Size change. Mean AAA sac size at 1-year (47.7 mm)
and 2-year (47.4 mm) follow-up was significantly reduced
compared with the reference scan (50.5 mm). These differ-
ences were lost by the 3-year (49.8 mm) follow-up, which
suggests delayed sac growth and re-expansion (Fig 1). The
proportion of patients with change in aneurysm size in
comparison with the reference scan at each time point is
shown in Fig 2. With longer follow-up a larger proportion
of patients exhibited an expanding aneurysm sac compared
with the reference scan. By 4 years, 37% of patients exhib-
ited significant enlargement of the aneurysm sac, whereas
only 21% showed significant size reduction.
At last follow-up, sac enlargement or re-expansion was
observed in 12 patients and sac shrinkage in 10 patients. All
but one of the enlargements was delayed in onset for at least
3 years after implantation. One sac enlargement was de-
tected at the 2-year follow-up examination (Fig 3). This is
in contrast to sac regression, which was usually observed
early, and noted within 12 months in 13 patients (Fig 4).
One patient was even noted to have a significant sac reduc-
tion at 1 month compared with the preoperative CT scan,
Fig 1. Average abdominal aortic aneurysm sac size at each fol-
low-up interval. *P  .05 compared with 1 month value.
Fig 2. Percentage of patients with enlarged, reduced, or stable
abdominal aortic aneurysm sac size at each follow-up interval
compared with baseline measurement.
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It is noteworthy that three sac enlargements were re-
expansions after initial shrinkage of more than 5 mm. In
one patient the sac had regressed by 10 mm by the 6-month
follow-up, with slow re-expansion to baseline by the fourth
year (Fig 5). In the second patient the sac regressed from 55
mm to 48 mm by the 6-month follow-up, and slowly
re-expanded to 54 mm at 4 years. In the third patient the
sac had shrunk from 49 mm to 42 mm at 6 months, only to
re-expand to 47 mm at 3 years, and to 49 mm at 4 years.
A Kaplan-Meier estimate of probability of freedom
from sac enlargement as compared with the reference scan
was 97% at 2 years, 86% at 3 years, and 57% at 4 years (Fig
6). This method of comparison, however, does not take
into consideration those sacs that re-expanded after initial
regression, because the last aneurysm size did not differ
significantly from the reference value. A Kaplan-Meier es-
timate of probability of freedom from sac enlargement as
Fig 3. Serial computed tomography scans demonstrate
implantation of the Excluder device.
Fig 4. Serial computed tomography scans demonstrate
implantation of the Excluder device.compared with the reference scan or the smallest size at any
follow-up time point was 95%, 80%, and 43%, respectively,
for the same periods of observation (Fig 7). Both plots
indicate frequent expansion rates after the third year of
observation.
Endoleak effects. There were no type I or type III
endoleaks. A type II endoleak was detected in eight patients
(18%), with spontaneous resolution in five patients. One
patient with spontaneous resolution of a type II endoleak at
12 months exhibited delayed sac growth at the 4-year
follow-up visit. After 3 years of stable size, the sac enlarged
from 52 mm to 62 mm in 1 year without any evidence of
endoleak at either CT scanning or angiography. All three
patients with persistent endoleak underwent angiography
for attempted treatment. In one patient the endoleak could
not be identified; in the other two patients coil emboliza-
tion of lumbar endoleaks was successful. In both of these
patients, however, the leak failed to be completely obliter-
ated at long-term follow-up. All three patients exhibited sac
ual increase in abdominal aortic aneurysm sac size after
d decrease in abdominal aortic aneurysm sac size aftergradrapi
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these patients underwent conversion to open repair; the
other two patients are still being observed.
In nine of 12 patients sac expansion developed, ranging
from 6 to 11 mm, in the absence of any active endoleak.
History of endoleak was not associated with sac enlarge-
ment (P  .08, 2). This may represent a type II error due
to the small number of patients. Early sac shrinkage by
either 6 months or 1 year did not provide any protective
effects against delayed aneurysm expansion. Smaller aneu-
rysms (5 cm) exhibited a higher incidence of sac shrink-
age than did larger aneurysms (P  .046).
DISCUSSION
Several recent reports have shown that change in aneu-
rysm size after EVAR is endograft-dependent.2,8,9 The
Excluder and AneuRx devices had a sharply lower incidence
of shrinkage compared with the other endografts. The
clinical significance of these changes, however, is not en-
tirely clear. Although shrinkage of the sac may be reassur-
ing, it does not necessarily indicate complete exclusion,
inasmuch as some patients may show regression in the
Fig 5. Serial computed tomography scans demonstrate i
by re-expansion.
Fig 6. Probability of freedom from aneurysm sac enlargement
compared with baseline after repair of abdominal aortic aneurysm
with the Excluder device.presence of small endoleaks.9,10 Reduction in sac size is not
universal, and many patients show no significant change
over a long period despite adequate exclusion by most
methods of assessment. A stable sac is clinically benign, and
has even been considered desirable in the early endograft
experience, because it averts inducing stresses on modular
junctions with the changing geometry of a shrinking
AAA.11 Concern during follow-up is usually elicited only
by an enlarging sac, because it has most often been associ-
ated with significant endoleak and anticipation of possible
rupture. Though infrequent, an enlarging sac without de-
monstrable endoleak has been reported on several occa-
sions,3,12,13 and has been attributed to “endotension,” a
state of increased pressure in the excluded sac. The inci-
dence of such enlargement has been unusual, representing
a small fraction of patients treated with EVAR.2,10,14,15
This is the first report indicating that a significant
number of patients treated with a single endograft exhibit
this unusual expansion over time, even in the absence of
endoleak. Nearly 40% of the patients treated with an Ex-
cluder device had significant sac enlargement compared
with baseline diameter measurement by the fourth fol-
decrease in abdominal aortic aneurysm sac size, followed
Fig 7. Probability of freedom from aneurysm sac growth or re-
expansion after repair of abdominal aortic aneurysm with the
Excluder device.nitial
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ated with any untoward clinical events. Our only conver-
sion so far was in a patient with a known endoleak from a set
of lumbar arteries in the neck of the sac that could not be
treated noninvasively.
The pathogenesis of sac enlargement with the Excluder
endograft is not well known. Several open conversions in
the United States and Europe have indicated the presence
of highly viscous fluid or gel in the sac, without evidence of
unrecognized endoleak. This has been termed by Risberg
et al3 as a sac “hygroma.” Whether this represents an
exudate of fluid through the graft material or from another
source remains to be determined. Microleaks at suture
points between stent and fabric noted with other en-
dografts16 have never been demonstrated with the Ex-
cluder device, which relies on a bonded film to fix the
components, rather than manually placed sutures. This
seems to be an unlikely source for the observed enlarge-
ment. Many other theories have been advanced, including
an active fibrinolytic state that attracts fluid accumulation
into the sac.17-20 However, the absence of similar behavior
with other endografts where clot absorption is also proba-
bly associated with a fibrinolytic state seems to favor trans-
gression of fluid through the fabric, analogous to the
subcutaneous implantation of expanded polytetrafluoroe-
ethylene in the periphery.21,22 Upcoming modifications to
the graft material to reduce permeability are expected soon,
and should help delineate whether this is the cause of sac
enlargement. Since this is the most likely theory for this
behavior, this change may resolve the issue satisfactorily.
When sac enlargement coexists with endoleak, treat-
ment has been directed at treating the endoleak, and if
unsuccessful, conversion to open repair has been advocated
to avert late rupture. No clear mandate exists, however, for
conversion in patients with expansion of the sac in the
absence of endoleak. Rupture of the sac in these patients
may not be of major clinical significance. Since endoleak
cannot always be reliably ruled out, the tendency is to err on
the safe side, and convert to an open procedure. In addi-
tion, possible concern about short necks becoming effaced
with enlarging sacs, although unproved, adds a theoretical
disadvantage to long-term observation. These concerns
may result in a number of late conversions if an endograft is
associated with a large number of expanding sacs, as ap-
pears to be the case with the Excluder device. Alternative
strategies, such as emptying the sac by means of aspiration,
exploration and reclosing of the sac, or performing a win-
dow in the sac laparoscopically, are being explored by
several investigators (M. R. van Sambeek, personal commu-
nication, 2003).3 The long-term benefits of such strategies
remain unconfirmed. We have continued to observe most
of our patients, because of slow growth and limited size of
the enlarged sac. Some are patients at high risk in whom
long-term observation may be justifiable.
Despite the large number of patients exhibiting en-
largement or re-expansion, the clinical results remain good
at 4 years, with no migration, rupture, disconnection of
limbs, or occlusion. The excellent early results23 and thegood late clinical outcomes continue to justify the use of
this device, especially in patients at high risk with shortened
life expectancy. In addition, physical characteristics of the
device, such as low profile and flexibility, make it more
suitable for use in certain anatomic situations than other
available devices. Initial shrinkage, however, should not
provide a false sense of security; we noted later sac expan-
sion in several patients who had initial reduction in sac size.
This should underscore the importance of vigilant fol-
low-up for the life of the patient. The expansion process is
slow, and does not manifest itself clearly until the 4-year
follow-up. This may be due to a slow transudation of fluid
or the use of a crude and insensitive method of measuring
enlargement, such as enlargement of the diameter of the sac
by 5 mm before being considered significant. Volume
measurements may be more sensitive, and may enable
identification of enlargement at an earlier stage.24
The current report is limited by the relatively small
number of patients with 4-year follow-up. Awaiting the
national trial data report will be important to place the
incidence of this observation into proper perspective. Nev-
ertheless, the present study raises some concern that the
incidence of late sac enlargement with the Excluder device
may be higher than anticipated, exceeding what has been
reported with other devices. Whether this observation will
translate into any kind of clinical sequelae, however, re-
mains unclear. Until long-term behavior of this phenome-
non is better understood, we recommend close follow-up
of patients with sac expansion at shorter intervals, with CT
and other adjunctive imaging methods, to identify and treat
endoleak, if present. Conversion to open repair should be
considered in the presence of an endoleak that is recalci-
trant to catheter-based techniques, at the request of pa-
tients or rapid expansion of the sac. Our patients have not
manifested any clinical consequences at 4 years after im-
plantation, with the only conversion being to treat an
unresolved endoleak. Investigations into the pathogenesis
of this phenomenon, and strategies to deal with its sequelae
remain an important challenge.
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James May, MD, MS, FRACS, Sydney, Australia
By careful analysis of progressive computed tomography scans
during follow-up, Cho et al identified a staggering probability of
freedom from sac growth or re-expansion at 4 years of only 43%
after endovascular abdominal aortic aneurysm (AAA) repair with
the Excluder device (W. L. Gore & Associates). Inasmuch as all
measurements were prospectively performed by a single, experi-
enced endovascular surgeon, the intraobserver error, if tested, may
well have been less than the 5 mm arbitrarily chosen as significant.
It is possible therefore that the figure for freedom from sac growth
or re-expansion at 4 years may be even lower than 43%.
Of greater interest and concern is their finding that sac expan-
sion occurred in the absence of active endoleak in nine of 12
patients; the remaining three patients had type II endoleaks. Al-
though the cause of the aneurysm enlargement is not known, it
must be assumed, for patient safety, to be due to raised intrasac
pressure or endotension. There have been anecdotal reports of
endotension previously, but this is the first report of endotension
occurring in almost half of patients who received a single type of
endograft.While the method of the study is exemplary, one might
question the interpretation of the findings. The authors have made
an important observation, but appear to be intent on putting a
favorable spin on it. They state that the excellent early results, as
well as good late clinical outcomes, continue to justify the use of
this device. Considering that a patient with an expanding AAA sac
after endovascular repair is probably at the same risk for rupture as
if nothing had been done to treat the aneurysm in the first place, it
is difficult to recommend a device with a known probability of
failure of 57% at 4 years when there are other devices without this
impediment.
The freedom from rupture in this series would appear to be
related to the small size of the aneurysms at graft implantation
(mean, 50.5 mm) and the reduction in size of some aneurysms
before undergoing expansion. If the same rate of expansion con-
tinues as occurred in the third and fourth years of follow-up in this
study or the device is implanted in larger aneurysms, freedom from
rupture cannot be expected to last. Endovascular AAA repair
continues to evolve. If a problem is detected it needs to be
addressed, not minimized.INVITED COMMENTARY
Mark Fillinger, MD, Lebanon, NH
The study by Cho et al raises a number of interesting points,
mostly reflecting questions that remain unanswered about endo-
vascular repair in general. For example, there is nearly universal
agreement that aneurysm enlargement following endovascular re-
pair should be taken seriously. There is a lack of agreement,
however, about what specific steps to take when an aneurysm
enlarges with an endograft in place, especially if there is no obvious
endoleak. It is logical that aneurysm growth reflects pressurewithin the sac and, thus, a failure to fully “depressurize” the sac.
Many also assume that aneurysm growth with an endograft in place
implies a risk of rupture equivalent to that of an unrepaired
aneurysm, but this remains controversial.
This controversy is reflected in the Cho et al article, in which
the authors appropriately report a higher-than-expected incidence
of aneurysm enlargement with a specific endograft. As in many
reports regarding endotension, however, the small patient num-
